Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Colace (sodium), Surfak (calcium); many generics OTC (1) ·
Dulcolax, Correctol, Bisac-Evac (1) ·
Generic; huge OTC presence (1) ·
Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon (1) ·
Kristalose, Constulose, Generlac, Enulose (1) ·
MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) ·
Ultram (IR), Ultram ER, ConZip ER (1)
classes:
potent non-selective)]] (1) ·
weak μ-agonist with serotonin/norepinephrine reuptake inhibition)]] (1) ·
[[:Category:Analgesics|Analgesic]] (2) ·
[[:Category:Antioxidants|Antioxidant]] (1) ·
[[:Category:Bowel_preparation_agents|Bowel preparation agent]] (1) ·
[[:Category:Diphenylmethane_laxatives|Diphenylmethane laxative]] (1) ·
[[:Category:Disaccharides|Non-absorbable disaccharide]] (1) ·
[[:Category:Hepatic_encephalopathy_treatments|Hepatic encephalopathy treatment]] (1) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID (1) ·
[[:Category:Opioid analgesics|Opioid analgesic (atypical (1) ·
[[:Category:Osmotic_laxatives|Osmotic laxative]] (2) ·
[[:Category:Schedule IV controlled substances|Schedule IV controlled substance]] (1) ·
[[:Category:Stimulant_laxatives|Stimulant laxative]] (1) ·
[[:Category:Stool_softeners|Stool softener]] (1) ·
[[:Category:Surfactants|Surfactant]] (1) ·
[[:Category:Vitamins|Vitamin]] (1) ·
[[:Category:Water-soluble_vitamins|Water-soluble vitamin]] (1)
mechanism:
None (5) ·
'"`UNIQ--vote-00001067-QINU`"' Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses'"`UNIQ--ref-00001068-QINU`"'. (1) ·
'"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)
uses:
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) ·
'"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"' (1) ·
'"`UNIQ--vote-00001069-QINU`"', '"`UNIQ--vote-0000106A-QINU`"' (1) ·
'"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"' (1) ·
'"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1) ·
'"`UNIQ--vote-00001341-QINU`"', '"`UNIQ--vote-00001342-QINU`"' (1)
starting dose:
100-200 mg PO once or twice daily; pediatric weight-based (1) ·
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses (1) ·
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) ·
Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) ·
Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) ·
General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) ·
IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days (1)
preparations:
10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) ·
100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) ·
17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) ·
5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx (1) ·
50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC (1) ·
Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) ·
IR tablets 50 mg; ER tablets 100, 200, 300 mg (Ultram ER, ConZip); oral solution 5 mg/mL; combination products with acetaminophen (Ultracet) (1)
fda max:
200 mg/day (typical adult oral) (1) ·
30 mg/d for short-term use (1) ·
400 mg/day (IR, adult); 300 mg/day (ER); 300 mg/day in elderly >75 years (1) ·
Indication-specific; bowel prep regimens reach 4 L cumulative (1) ·
Indication-specific; HE may require high-volume dosing (1) ·
UL 2000 mg/d in adults (1) ·
~500 mg/d typical (1)
routes:
onset:
1-3 days (1) ·
30-60 minutes (IR) (1) ·
30-60 minutes (oral); rapid relief in acute gout (1) ·
Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) ·
Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) ·
Days for symptom improvement in scurvy (1) ·
PO 6-12 hours; PR 15-60 minutes (1)
duration: (Click arrow to add another value)
halflife:
4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
Not meaningfully described (1) ·
Not meaningfully described (negligible systemic absorption) (1) ·
Not meaningfully described — lactulose is not significantly absorbed (1) ·
Tramadol 6-7 hours; M1 active metabolite 7-9 hours'"`UNIQ--ref-0000001D-QINU`"' (1) ·
Variable; effect dependent on local intestinal action rather than systemic kinetics'"`UNIQ--ref-0000106B-QINU`"' (1) ·
~10-20 days (steady-state body pool); single dose plasma ~2 hours (1)
bioavailability:
<0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) ·
<3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) ·
Local action; minimal systemic effect (1) ·
Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' (1) ·
~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~70-90% at typical doses; saturable at high doses (>500 mg) (1) ·
~75% (IR, rises with multi-dose administration due to saturable first-pass)'"`UNIQ--ref-0000001E-QINU`"' (1)
pregnancy:
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable for short-term use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at routine doses; routinely supplemented in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) ·
OTC in US (3) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (federally scheduled 2014); some states schedule higher'"`UNIQ--ref-0000001F-QINU`"' (1)
Showing below up to 7 results in range #1 to #7.